Pfizer admits myocarditis risk for 5-12 yr-olds requires 5-yr study:
"The number of participants in the current clinical development program is too small to detect any potential risks of myocarditis associated with vaccination. Long-term safety of COVID-19 vaccine in participants 5 to <12 years of age will be studied in 5 post-authorization safety studies, including a 5-year follow-up study to evaluate long term sequelae of post-vaccination myocarditis/pericarditis."
(Pfizer: VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE BRIEFING DOCUMENT Meeting Date: 26 October 2021)
99.998737 percent survival rate.
In the 12- to 17-year-old age group, 23,871 adverse events, including 1,453 rated as serious and 31 deaths were reported to VAERS. In the 11- to 17-year-old age group:
• 60 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
• 563 reports of myocarditis and pericarditis (heart inflammation).
• 139 reports of blood clotting disorders.
Over 15,000 doctors and scientists have signed the International Alliance of Physicians and Medical Scientists declaration stating:
Long term safety of the current COVID vaccines in children cannot be determined prior to instituting such policies. Without high-powered, reproducible, long term safety data, risks to the long-term health status of children remain too high to support use in healthy children.
Children risk severe, adverse events from receiving the vaccine. Permanent physical damage to the brain, heart, immune and reproductive system associated with SARS-CoV-2 spike protein-based genetic vaccines has been demonstrated in children.
To make a donation for using this web site, click the go fund me logo.